Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: Correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings-preliminary results

Radiology

Volumn 249, Issue 2, 2008, Pages 471-482

  Makkat, Smitha ^a   Luypaert, Robert ^a   Stadnik, Tadeusz ^a   Bourgain, Claire ^a   Sourbron, Steven ^c   Dujardin, Martine ^a   De Greve, Jacques ^b   De Mey, Johan ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GADOLINIUM PENTETATE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD FLOW; BREAST TUMOR; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR BLOOD FLOW; CHI SQUARE DISTRIBUTION; COMPUTER ASSISTED DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); NONPARAMETRIC TEST; PATHOLOGY; PROTO ONCOGENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; GENES, ERBB-2; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 56149117841     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2492071147     Document Type: Article

References (47)

1. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
2. Degani H, Chetrit-Dadiani M, Bogin L, Furman-Haran E. Magnetic resonance imaging of tumor vasculature. Thromb Haemost 2003;89:25-33.
3. Kuhl CK, Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999;211:101-110.
4. Brix G, Kiessling F, Lucht R, et al. Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series. Magn Reson Med 2004;52:420-429.
5. Buckley DL, Drew PJ, Mussurakis S, Monson JR, Horsman A. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 1997;7:461-464.
6. Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999;10:260-266.
7. Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 2003;18:467-477.
8. Pollitt MJ, Hanby AM, Horgan K, Murphy CE, Jones PF, Speirs V. Angiogenesis in breast cancer: how should we measure this? [review]. Oncol Rep 2005;13:931-936.
9. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998;16:462-469.
10. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-1646.
11. Blackwell KL, Dewhirst MW, Liotcheva V, et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res 2004;10:4083-4088.
12. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005;97:172-187.
13. Sourbron S, Dujardin M, Luypaert R, et al. Quantification of cerebral tumor perfusion and permeability with a deconvolution analysis of T1-weighted bolus tracking data [abstr]. In: Proceedings of the 12th Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2004; 188.
14. Sourbron S, Dujardin M, Makkat S, Luypaert R. Pixel-by-pixel deconvolution of bolus-tracking data: optimization and implementation. Phys Med Biol 2007;52:429-447.
15. Makkat S, Sourbron S, Dujardin M, Van Schuerbeek P, Luypaert R, Stadnik T. Deconvolution-based contrast enhanced MR imaging of breast tumors for perfusion quantification: a feasibility study [abstr]. In: Proceedings of the 13th Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2005; 743.
16. Makkat S, Luypaert R, Sourbron S, Stadnik T, De Mey J. Quantification of perfusion and permeability in breast tumors with a deconvolution- based analysis of second bolus T1-DCE data. J Magn Reson Imaging 2007;25:1159-1167.
17. Osanai T, Wakita T, Gomi N, Takenaka S, Kakimoto M, Sugihara K. Correlation among intratumoral blood flow in breast cancer, clinicopathological findings and Nottingham prognostic index. Jpn J Clin Oncol 2003;33:14-16.
18. th Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2006; 1797.
19. Köstler H, Ritter C, Lipp M, Beer M, Hahn D, Sandstede J. Prebolus quantitative MR heart perfusion imaging. Magn Reson Med 2004;52:296-299.
20. Sourbron S, Luypaert R, Van Schuerbeek P, Dujardin M, Stadnik T, Osteaux M. Deconvolution of dynamic contrast-enhanced MRI data by linear inversion: choice of the regularization parameter. Magn Reson Med 2004;52:209-213.
21. Dujardin M, Sourbron S, Luypaert R, Verbeelen D, Stadnik T. Quantification of renal perfusion and function on a voxel-byvoxel basis: a feasibility study. Magn Reson Med 2005;54:841-849.
22. Gribbestad IS, Nilsen G, Fjøsne HE, Kvinnsland S, Haugen OA, Rinck PA. Comparative signal intensity measurements in dynamic gadoliniumenhanced MR mammography. J Magn Reson Imaging 1994;4:477-480.
23. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: a retrospective analysis of 176 cases. Cancer 1990;65:1794-1800.
24. Bourgain C, Smitz J, Camus M, et al. Human endometrial maturation is markedly improved after luteal supplementation of gonadotrophin-releasing hormone analogue/human menopausal gonadotrophin stimulated cycles. Hum Reprod 1994;9:32-40.
25. Fisher ER, Anderson S, Dean S, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 2005;103:164-173.
26. Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001;195:422-428.
27. McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 2002;117:935-943.
28. Nabavi DG, Cenic A, Craen RA, et al. CT assessment of cerebral perfusion: experimental validation and initial clinical experience. Radiology 1999;213:141-149.
29. Craft PS, Harris AL. Clinical prognostic significance of tumour angiogenesis. Ann Oncol 1994;5:305-311.
30. Mussurakis S, Buckley DL, Horsman A. Prediction of axillary lymph node status in invasive breast cancer with dynamic contrastenhanced MR imaging. Radiology 1997;203:317-321.
31. Teifke A, Behr O, Schmidt M, et al. Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. Radiology 2006;239:351-360.
32. Tuncbilek N, Karakas HM, Okten OO. Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. Eur J Radiol 2005;53:199-205.
33. Stomper PC, Herman S, Klippenstein DL, et al. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology 1995;197:387-395.
34. Fischer U, Kopka L, Brinck U, Korabiowska M, Schauer A, Grabbe E. Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. Eur Radiol 1997;7:1002-1005.
35. Szabó BK, Aspelin P, Kristoffersen Wiberg M, Tot T, Boné B. Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol 2003;13:2425-2435.
36. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992;340:1120-1124.
37. Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF family gene expression. Mod Pathol 2005;18:143-152.
38. Ludovini V, Sidoni A, Pistola L, et al. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat 2003;81:159-168.
39. Ali SH, O'Donnell AL, Balu D, et al. Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res 2000;60:7094-7098.
40. Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004;10:1706-1716.
41. Kumar R, Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin Oncol 2001;28:27-32.
42. Vogl G, Bartel H, Dietze O, Hauser-Kronberger C. HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer. Appl Immunohistochem Mol Morphol 2006;14:138-145.
43. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-1530.
44. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-3664.
45. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-153.
46. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-157.
47. Knopp MV, Bourne MW, Sardanelli F, et al. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. AJR Am J Roentgenol 2003;181:663-676.